NOT KNOWN DETAILS ABOUT MBL77

mutations supplied The reality that, as discussed under, CLL therapy is based on the existence or absence of those mutations. The current consensus is that, in addition to clonal mutations, subclonal mutations that has a variant allelic frequency ranging from five to 10% (and therefore down below the edge of detection by traditional molecular metho

mutations supplied The reality that, as discussed under, CLL therapy is based around the presence or absence of these mutations. The existing consensus is usually that, apart from clonal mutations, subclonal mutations using a variant allelic frequency starting from 5 to ten% (and so underneath the brink of detection by common molecular approaches)